Anoop K Enjeti

15PUBLICATIONS
106CO-AUTHORS
Regenerative medicine (incl. stem cells)Gene and molecular therapyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Toxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Aug 27, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Oct 17, 2024
Certainty in uncertainty: Determining the rate and reasons for reclassification of variants of uncertain significance in haematological malignancies.

Anoop K Enjeti, Natasha Walker, Oliver Fahey

|Sep 03, 2024
Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study.

Emma Verner, Amanda Johnston, Nalini Pati

|Jun 19, 2024
Development of the treatment preference in myelodysplasia questionnaire for clinicians, carers, and patients.

Robert Morlock, Chun Fong, Francesco Castaldi

|Jun 19, 2024
Real-world study of the use of azacitidine in myelodysplasia in Australia.

Anoop Enjeti, Asma Ashraf, Vincent Caillet

Pageof 3

Frequent Collaborators

2 joint publications

Amy E DeZern

2 joint publications

Elizabeth A Griffiths

2 joint publications

Luca Lanino

2 joint publications

Benjamin Rolles